Collaboration for Diabetes Treatment Access
TheracosBio is excited to announce a pivotal partnership with PBA Health, focusing on improving access to diabetes treatment through affordable medication options. The newly available medication, BRENZAVVY (bexagliflozin), is an FDA-approved oral medication specifically designed for individuals with type 2 diabetes. The collaboration with PBA Health marks a significant opportunity for thousands of independent community pharmacies to stock this essential medication.
Understanding BRENZAVVY in Diabetes Management
BRENZAVVY is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor that has shown effectiveness in treating type 2 diabetes. With its introduction to the pharmacies supported by PBA Health, patients can gain access to an affordable alternative to other medications in the SGLT2 class. This cooperation aims to alleviate the financial burden often associated with diabetes treatment, thereby promoting better health outcomes for patients.
Importance of Independent Community Pharmacies
Independent community pharmacies play an invaluable role in the healthcare system. They are recognized for their personalized care and commitment to serving local communities. The introduction of BRENZAVVY through PBA Health enhances the ability of these pharmacies to provide essential medications to patients who may struggle to afford them. As president and CEO of TheracosBio, Brian Connelly expressed enthusiasm for this initiative, noting the importance of supporting pharmacists in managing their patients' diabetes effectively.
Cost Benefits for Patients
One of the notable advantages of BRENZAVVY is its affordability. Designed with cost in mind, the medication can be obtained for significantly less than many comparable diabetes medications — in fact, it can be up to 90% less expensive for a month’s supply. For individuals on a fixed income, this price reduction can be a game-changer, allowing them to manage their treatment more effectively without compromising their financial stability.
How to Take BRENZAVVY
BRENZAVVY is administered as a 20 mg oral tablet, recommended to be taken once daily. Patients have the flexibility to take it with or without food, making it convenient to incorporate into their daily routine. This accessibility is essential for those managing a chronic condition like diabetes, as adherence to medication is vital for effective treatment.
Clinical Evidence Supporting Efficacy
Clinical trials have demonstrated that BRENZAVVY effectively reduces hemoglobin A1c and fasting blood sugar levels within 24 weeks of treatment. This can occur whether the medication is used alone or in conjunction with other treatments, such as metformin. While it is not approved for weight loss or blood pressure reduction, some patients have reported modest decreases in both, underscoring the medication’s overall benefits.
Commitment to Patient Safety
Patient safety is always a top priority when introducing new medications. BRENZAVVY comes with specific contraindications; it is not recommended for individuals with type 1 diabetes or those who are hypersensitive to any component of the medication. Common side effects include urinary and genital infections, but additional serious side effects can occur, which leads TheracosBio to prioritize thorough testing and monitoring for all patients.
Staying Informed About Potential Risks
Healthcare providers will counsel patients on the risks associated with BRENZAVVY, including diabetic ketoacidosis and urinary tract infections. Adjustments may need to be made for individuals taking insulin or other medications that affect blood sugar levels. Education for both patients and healthcare professionals is crucial to mitigate these risks effectively.
About TheracosBio and PBA Health
Established in 2004, TheracosBio aims to provide novel therapeutics at affordable prices, making healthcare accessible. PBA Health has been a respected leader in pharmacy supply chain solutions since 1983, supporting independent community pharmacies in delivering the best care to their patients.
With this partnership, TheracosBio and PBA Health are set to pave the way for better diabetes management, making a significant difference in the lives of patients across the country.
Frequently Asked Questions
What is BRENZAVVY?
BRENZAVVY is an FDA-approved oral medication used to treat type 2 diabetes, specifically designed to help manage blood sugar levels.
How can I access BRENZAVVY?
BRENZAVVY will be available at participating independent community pharmacies that are part of PBA Health's network.
Why is this partnership significant?
This partnership allows for greater access to affordable diabetes medication for patients who may struggle to afford existing treatments.
What are the common side effects of BRENZAVVY?
Common side effects include urinary tract infections and genital infections. Patients should discuss any concerns with their healthcare provider.
How does BRENZAVVY compare cost-wise to other diabetes medications?
BRENZAVVY can be obtained for up to 90% less than many existing SGLT2 medications, providing a cost-effective option for patients.
